A revised Tafenoquine dose to improve radical cure for Vivax malaria -Tafenoquine dosing revised

Abstract

Tafenoquine (TQ), as a single dose regimen, has significant advantages over the longer courses of primaquine (PQ) needed to achieve radical cure of P. vivax. The current data available show that the recommended fixed dose of 300mg TQ in adults is too low and compromised by a lack of weight-based dosing. To ensure maximal impact on health outcomes, the recommended dose for TQ must be optimized for clinical practice. Our study will assess the efficacy and safety of a higher weight based TQ dose regimen.